3-ethoxypropyl 6-((tert-butoxycarbonyl)amino)hexanoate (7)
3-ethoxypropan-1-ol (1.62 mg; 1.56 mmol) and 6-((tert-butoxycarbonyl)amino)hexanoic acid (300 mg; 1.3 mmol) were dissolved in THF (30 ml). A spatula tip of Novozyme 435 was added and the solution was stirred for 8 hours on a rotavapor at 70 ˚C and 250 mbar. Novozyme was filtered off and the crude product purified using column chromatography (SiO2, 0-30 % EtOAc in Heptanes). Yield = 362 mg, 1.14 mmol; ɳ = 88 %. 1 H NMR (400 MHz, CDCl3) δ: 1.19 (t, 3H, CH2CH3), 1.34-1.88 (m, 6H, CH2), 1.44 (s, 9H, CH3), 1.91 (q, 2H, CH2), 2.31 (t, 2H, CH2-C=O), 3 .12 (t, 2H, NH-CH2), 3 
.50 (t, 4H, O-CH2), 4.16 (t, 2H, C=O-O-CH2), 4.73 (b, 1H, NH)
. 13 
6-(3-ethoxypropoxy)-6-oxohexan-1-aminium chloride (8)
3-ethoxypropyl 6-((tert-butoxycarbonyl)amino)hexanoate 7 (360 mg, 1.13 mmol) was dissolved in 4M HCl in dioxane (10 mL) and stirred for 8 hours at room temperature. Evaporation of the solvent yielded the product. Yield = 288 mg, 1.13 mmol; ɳ = >99 %. 1 H NMR (400 MHz, CDCl3) δ: 1.19 (t, 3H, CH2CH3), 1.45 (p, 2H, CH2), 1.67-1.89 (m, 6H, CH2), 2.33 (t, 2H, CH2-C=O), 3 .03 (t, 2H, NH3-CH2), 3 
Ethyl 3-(2-(1H-imidazole-1-carboxamido)-6-methyl-4-oxo-1,4-dihydropyrimidin-5-yl) propanoate (9)
Ethyl 3-(2-amino-6-methyl-4-oxo-1,4-dihydropyrimidin-5-yl)propanoate (1.09 g, 4.84 mmol) and carbonyldiimidazole (1.10 g, 6.78 mmol) were dissolved in dry chloroform (30 mL) and stirred at 60 ˚C for 16 h. The solution was allowed to cool to room temperature, washed with water (3 x 50 mL) and dried using MgSO4. The solvent was removed under vacuum. Yield = 1.50 mg, 4.70 mmol; ɳ = 97 %. 1 H-NMR (200 MHz, CDCl3) δ: 1.26 (t, 3H, CH2-CH3), 2.50 (s, 3H ,C-CH3), 2.63 (t, 2H, O=C-CH2-CH2), 2.77 (t, 2H, C=O-CH2-CH2), 4.11 (q, 2H, O-CH2-CH3), 7.01 (s, 1H, C=O-N-CH=CH), 7.60 (s, 1H, C=O-N-CH=CH), 8.84 (s, 1H, N-CH=N). 13 3-ethoxypropyl 6-(3-(5-(3-ethoxy-3-oxopropyl)-6-methyl-4-oxo-1,4 -dihydropyrimidin-2-yl)ureido)hexanoate (1) 6-(3-ethoxypropoxy)-6-oxohexan-1-aminium chloride 19 (288 mg, 1.14 mmol) and ethyl 3-(2-(1H-imidazole-1-carboxamido)-6-methyl-4-oxo-1,4-dihydropyrimidin-5-yl)propanoate 9 (435 mg, 1.36 mmol) were dissolved in chloroform (8 mL) and triethylamine (138 mg, 1.36 mmol) was added dropwise. The reaction mixture was stirred overnight at room temperature, the mixture was diluted with chloroform (20 mL) and washed with water (3 x 20 ml). The organic phase was dried using MgSO4 and filtered. The crude product was purified using column chromatography (SiO2, 0-5 % methanol in chloroform). Yield = 251 mg, 0.54 mmol; ɳ = 47 %. 1 Scheme S2. Synthesis of divalent UPy 2 3,3'-((2,2-dimethylpropane-1,3-diyl)bis(oxy))dipropanenitrile (10) Acrylonitrile (2.11 g, 111.9 mmol) and 2,2-dimethylpropane-1,3-diol (1.88 g, 18.1 mmol) were combined and 50 % NaOH aq. (0.1 mL) was added. The mixture was stirred overnight at room temperature, diluted with water (20 mL) and extracted with chloroform (3 x 30 mL). The organic phase was dried using MgSO4 and dried under vacuum to yield the target compound. 
((2,2-dimethylpropane-1,3-diyl)bis(oxy))bis(propane-3,1-diyl)bis(6-(3-(5-(3-ethoxy-3-oxopropyl)-6-methyl-4-oxo-1,4-dihydropyrimidin-2-yl)ureido)hexanoate) (2)
13,13-dimethyl-6,20-dioxo-7,11,15,19-tetraoxapentacosane-1,25-diaminium chloride 14 (530 mg, 1.02 mmol) and ethyl 3-(2-(1H-imidazole-1-carboxamido)-6-methyl-4-oxo-1,4-dihydropyrimidin-5-yl)propanoate 9 (717 mg, 2.24 mmol) were dissolved in chloroform (6 mL) and triethylamine (227 mg, 2.24 mmol) in chloforom (3 mL) was added dropwise. The reaction mixture was stirred overnight at room temperature, diluted with chloroform (20 mL), and washed with water (3 x 20 mL). The organic phase was dried using MgSO4 and filtered. The crude product was purified using column chromatography (SiO2 0-5% methanol in chloroform). Yield = 591 mg, 0.62 mmol; ɳ = 61 %. Tribocprotected compound (18) 3,3'-((2-((3-hydroxypropoxy)methyl)-2-methylpropane-1,3-diyl)bis(oxy))bis(propan-1-ol) 17 (100 mg, 0.34 mmol) and 6-((tert-butoxycarbonyl)amino)hexanoic acid (314 mg, 1.36 mmol) were dissolved in THF (30 mL). A spatula tip of Novozyme 435 was added and the solution was stirred at stirred for 8 hours on a rotavapor at 70 ˚C and 250 mbar. Novozyme was filtered off and the crude product purified using column chromatography (SiO2, 0-30 % EtOAc in Heptanes). Yield = 208 mg, 0.22 mmol; ɳ = 66 %. 1 
Trivalent UPy (3)
Trideprotected compound 19 (160 mg, 0.22 mmol) and ethyl 3-(2-(1H-imidazole-1-carboxamido)-6-methyl-4-oxo-1,4-dihydropyrimidin-5-yl)propanoate 9 (241 mg, 0.75 mmol) were dissolved in chloroform (6 mL). Triethylamine (76 mg, 0.75 mmol) in chloroform (4 mL) was slowly added. The mixture was stirred overnight, diluted with chloroform (30 mL) and washed with water (3 x 20 mL). The organic phase was dried using MgSO4 and concentrated under vacuum. The crude product was purified using column chromatography (SiO2, 0-5% MeOH in chloroform) followed by recycle GPC. Yield = 34 mg, 0.025 mmol; ɳ = 11.4 %. 1 Compounds 20-22 were made according to literature procedure (1).
Tetrabocprotected compound (23) 3,3'-((2,2-bis((3-hydroxypropoxy)methyl)propane-1,3-diyl)bis(oxy))bis(propan-1-ol) 22 (100 mg, 0.27 mmol) and 6-((tert-butoxycarbonyl)amino)hexanoic acid (314 mg, 1.36 mmol) were dissolved in THF (30 mL). A spatula tip of Novozyme 435 was added and the solution was stirred for 8 hours on a rotavapor at 70 ˚C and 250 mbar. Novozyme was filtered off and the crude product purified using column chromatography (SiO2, 0-30 % EtOAc in heptanes 
Tetradeprotected compound (25)
Tetrabocprotected compound 24 (200 mg, 0.16 mmol) was dissolved in HCl (4M in dioxane, 15 mL) and stirred for 16 hours. Evaporation of the solvent yielded the product. Yield = 158 mg, 0.16 mmol; ɳ = > 99 %. The product was used in the next reaction without further purification.
Tetravalent UPy (4)
Tetradeprotected compound 25 (150 mg, 156 mmol) and ethyl 3-(2-(1H-imidazole-1-carboxamido)-6-methyl-4-oxo-1,4-dihydropyrimidin-5-yl)propanoate 9 (248 mg, 0.78 mmol) were dissolved in chloroform (6 mL). Triethylamine (78 mg, 0.78 mmol) was slowly added and the mixture was stirred overnight. Chloroform was added (20 mL) and the mixture washed with water (3 x 20 mL) and dried using MgSO4. The crude product was purified using column chromatography (SiO2, 0-5 % MeOH in chloroform) and recycle GPC. Yield = 210 mg, 0.12 mmol; ɳ = 74 %. 
N,N'-(1,8-naphthyridine-2,7-diyl)didodecanamide (NaPy) 5 and N,N'-di-2-pyridylurea (DPU) 6
were synthesized according to literature procedures (2, 3). 
Concentration dependence of two-fold sensitivity
The two-fold sensitivity is dependent on the concentration of multivalent UPy, since that concentration determines the equilibrium between cyclic and linear species before NaPy is added (Fig. S7A) . At low multivalent UPy concentrations, intramolecular interactions lead to lower slopes during NaPy titration due to competition between cyclization and end-capping by NaPy. Therefore, the increase in free NaPy concentration at the equivalence point is less pronounced, resulting in a lower two-fold sensitivity. At high multivalent UPy concentrations, cyclic species are populated less, leading to less competition and higher two-fold sensitivities. Therefore, it is only at high multivalent UPy concentrations that an increase in multivalency leads to increased two-fold sensitivity. 
Determination of KUPy-UPy, KUPy-NaPy and EM1
Due to the expected high value of KUPy-UPy, it cannot be determined experimentally without changing the molecular structure to include a fluorescent dye (4). Since the molecular structure of the UPy moiety used in this study does not differ significantly from the reported structure, we assume that the value of KUPy-UPy is fixed at the reported value for 6-methylureidopyrimidinone groups in CHCl3 (KUPy-UPy = 6 × 10 7 M -1 ) (4). The correlated value of KUPy-NaPy was determined by first measuring 1 H NMR spectra of mixtures containing monovalent UPy 1 and NaPy 5, followed by fitting of the measured distribution of UPy-UPy and UPy-NaPy contacts with a simple binding model that includes UPy self-association and UPy-NaPy dimerization (KUPy-NaPy = (3 ± 0.2) × 10 6 M -1 ; Fig. S8A-B) . The determination of the EM of divalent UPy 2 was performed by measuring concentration dependent 1 H NMR spectra and subsequently fitting the data (Fig. S8C) . The data was analyzed with two different versions of the model, one in which all rings are considered strainless and in which only EM1 is used as a free parameter. In the second version the monomeric cycle is considered to be strained, so that two EMs are estimated (EM1 and EM2). Overlaying the best fits of both versions of the model with the data clearly shows that the second version fits considerably better (Fig. S8D, grey versus black lines) . To ensure that the addition of a model parameter is justified, an extra sum of squares F-test was performed which showed that it is highly likely that the second model is correct (F = 28, p = 1.95 × 10 -6 ) (5). The optimized values of EM1 and EM2 show that the monomeric cycle is slightly stabilized instead of being strained (EM1 = 5.3 ± 0.3 mM, EM2 = 0.3 ± 0.03 mM). However, as was the case with supramolecular buffering by divalent UPys, EM1 is the key parameter for buffering since oligomeric rings are formed only sparingly in the presence of stopper molecules (6) . Thus, only the optimized value of EM1 from the second version of the model is used as input parameter for the tri-and tetravalent UPy models.
Model description of tri-and tetravalent UPys with NaPy
Here we consider the aggregation of tri-and tetravalent molecules in the presence of a stopper molecule. As the stopper molecule limits the aggregation of the multivalent molecules, the models are limited to a degree of polymerization (DP) of four for the multivalent molecule. This limitation is also a practical one, as the number of species with a DP of four for the tetravalent molecule is 86 (including NaPy bound species), and the extrapolated amount of species for a DP of five is >100. First, we consider the self-association of a trivalent monomer. The monomer can cyclize only once, leaving a free binding group (Fig. S9) . When Kinter is sufficiently high, this cyclized species has a large energetic penalty due to the presence of a free binding group. Since the models are made for multivalent UPy molecules which have a high Kinter, we limit the species of the multivalent molecules to those which are fully, or to the highest degree, cyclized. Partially cyclized species are only included with the inclusion of monovalent stopper, vide infra. Interestingly, odd-numbered aggregates always leave a single free binding group upon cyclization. Since the energetic penalty for these species is so high with a large Kinter, they are so unfavorable that they are not populated at all. Thus, a trivalent, or any odd-valent, molecule with a high Kinter will always aggregate in evennumbered sizes in solution. As stated before, the inclusion of the stopper molecule leads to the inclusion of partially cyclized species as well, since free binding groups can now bind to the stopper (Fig. S9) . Thus, the number of species is greatly increased. With the stabilities of all species determined, the species were all included in two coupled mass balances: one for the trivalent UPy and one for NaPy (Equation S1; see Figs. S9 and S10). The balances cannot be solved analytically, since they are fourth and sixth order polynomials (UPy and NaPy, respectively). Therefore, the numerical function fsolve was used. To reduce computational time, a Jacobian matrix was supplied, which was calculated using the jacobian function from the symbolic math toolbox.
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Figure S10. Trivalent NaPy bound species included in the model and their corresponding stabilities.
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We now consider the aggregation of the tetravalent molecule. The tetravalent UPy monomer can cyclize twice, with both cyclization reactions having different statistical factors, which leads to a difference in the cycle stability. Again, we limit the model to fully cyclized species, since species with free binding groups will not be populated (Fig. S11) . As before, the number of species greatly increases upon introduction of the stopper (Fig. S12) . The mass balances were constructed in a similar manner as for the trivalent UPy model, and solved numerically using fsolve, which was supplied with an analytical Jacobian matrix.
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Figure S12. Tetravalent NaPy bound species included in the model and their corresponding stabilities.
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Figure S12 (Cont.). Tetravalent NaPy bound species included in the model and their corresponding stabilities.
Tetravalent UPy speciation during simulated NaPy titration
The titration simulations of the free NaPy concentration for all multivalent UPy constructs show that the tetravalent UPy displays the lowest slope (Fig. 2C ). This is attributed to the difference in stabilities for the formation of the two intramolecular cycles. The tetravalent UPy speciation during the titration simulation reveals that this difference in stabilities leads to a two-step process upon NaPy binding, opening the cycles one by one (Fig. S13) . Figure S13 . Simulated UPy speciation during titration with NaPy. The input parameters for the speciation are the same as in Fig. 2C and D. The colors of the lines correspond to the DP of the tetravalent UPy (1: blue, 2: red, 3: green).
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Fit of 1 H NMR data of trivalent UPy 3 and NaPy 5
The 1 H NMR spectra of the mixtures of trivalent UPy 3 and NaPy 5 showed three resonances for the UPy N-H protons (Fig. S14A) . Based on their concentration dependent behavior, these peaks were attributed to UPy-UPy contacts in monomeric rings of monomers and dimers, UPy-UPy contacts in oligomeric rings and linear species, and UPy-NaPy contacts. All trends in the data could be fitted well with the trivalent UPy model (Fig. S14B) . Gratifyingly, the model predictions, with parameter values set to those determined by the reference experiments, and the best fit show only a minimal difference. The best fit parameter values show that the values of KUPy-UPy and KUPy-NaPy are correlated linearly (Fig. S14C and D) .
As expected from the model prediction that trivalent UPy 3 will form dimers with two monomeric cycles at low concentrations, the fraction of UPy-UPy contacts in monomeric rings is close to 2/3 when no NaPy is present (Fig. S14B) . 
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Fit of 1 H NMR data of tetravalent UPy 4 and NaPy 5
The 1 H NMR spectra of tetravalent UPy showed a similar splitting of the UPy N-H protons, which could be attributed to UPy-UPy contacts in monomeric rings of monomers, UPy-UPy contacts in oligomeric rings and linear species, and UPy-NaPy contacts (Fig. S15A) . The data is equally well fitted as with the trivalent UPy model, and the fit parameter values show the same correlation ( Fig.  S15B-E) . 
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Model description and fit of the tetravalent UPy 4 and NaPy 5 titration using DPU 6
Since DPU can only self-associate or dimerize with NaPy, its mass balance is quite simple (Eq. S2a). The DPU mass balance was analytically solved for the free DPU concentration using Wolfram Mathematica (Eq. S2b), and subsequently substituted in the NaPy mass balance of the tetravalent UPy model. That NaPy mass balance was also modified with the addition of the DPUNaPy dimer. The mass balance of the tetravalent UPy was not modified, since DPU has no interaction with UPy groups. With the DPU aggregation incorporated in the NaPy mass balance, both the tetravalent UPy and NaPy mass balances were solved numerically using fsolve. The model was used to perform a global fit of the data shown in the main text and here ( Fig. 4 and S16), using as fit parameters the equilibrium dimerization constants KDPU-NaPy and KDPU-DPU. . UPy fractions, residuals, and NaPy fractions of the best fit (lines) and based on 1 H NMR spectra during titration. The starting concentrations of both multivalent UPy and NaPy are 3 mM (A) and 10 mM (B). Of the NaPy fractions, only the free NaPy fraction could be assigned from the spectra. 
